Lymphoplasmacytic Lymphoma clinical trials

Explore recruiting lymphoplasmacytic lymphoma clinical trials.

Recruiting lymphoplasmacytic lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lymphoplasmacytic Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Poland, France, Spain, Czechia, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma

France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies

France, Poland, Romania, Italy, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Lymphoplasmacytic Lymphoma trials by city

Lymphoplasmacytic Lymphoma clinical trials

Recruiting lymphoplasmacytic lymphoma studies right now

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

Also recruiting in Europe

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma

Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies

Lymphoplasmacytic Lymphoma trials by city

Other conditions